Advanced Enzyme Technologies Ltd
Advanced Enzyme Technologies Limited is engaged in the business of manufacturing and sales of enzymes.[1]
- Market Cap ₹ 3,078 Cr.
- Current Price ₹ 275
- High / Low ₹ 324 / 225
- Stock P/E 28.8
- Book Value ₹ 110
- Dividend Yield 1.45 %
- ROCE 12.3 %
- ROE 9.18 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 19.5%
Cons
- The company has delivered a poor sales growth of 6.69% over past five years.
- Company has a low return on equity of 12.0% over last 3 years.
- Promoter holding has decreased over last 3 years: -8.01%
- Working capital days have increased from 195 days to 359 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
171 | 219 | 239 | 222 | 293 | 329 | 391 | 420 | 444 | 502 | 529 | 541 | |
109 | 130 | 189 | 131 | 155 | 177 | 226 | 236 | 241 | 269 | 327 | 384 | |
Operating Profit | 62 | 90 | 50 | 91 | 138 | 152 | 165 | 184 | 203 | 233 | 203 | 156 |
OPM % | 36% | 41% | 21% | 41% | 47% | 46% | 42% | 44% | 46% | 46% | 38% | 29% |
3 | 4 | 1 | 1 | -3 | 3 | 1 | 5 | 6 | 9 | 6 | 21 | |
Interest | 12 | 10 | 13 | 9 | 8 | 4 | 9 | 5 | 4 | 3 | 3 | 2 |
Depreciation | 6 | 8 | 10 | 9 | 9 | 13 | 18 | 21 | 26 | 29 | 35 | 35 |
Profit before tax | 48 | 76 | 28 | 74 | 118 | 137 | 139 | 162 | 179 | 210 | 171 | 140 |
Tax % | 29% | 34% | 23% | 31% | 35% | 32% | 33% | 28% | 26% | 28% | 28% | 26% |
Net Profit | 34 | 50 | 21 | 51 | 77 | 93 | 94 | 116 | 133 | 151 | 124 | 104 |
EPS in Rs | 3.22 | 4.52 | 1.85 | 4.60 | 6.97 | 8.20 | 8.07 | 9.95 | 11.58 | 13.06 | 10.70 | 9.45 |
Dividend Payout % | 1% | 7% | 6% | 4% | 3% | 5% | 6% | 6% | 5% | 7% | 9% | 42% |
Compounded Sales Growth | |
---|---|
10 Years: | 9% |
5 Years: | 7% |
3 Years: | 7% |
TTM: | 2% |
Compounded Profit Growth | |
---|---|
10 Years: | 8% |
5 Years: | 3% |
3 Years: | -6% |
TTM: | -10% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 5% |
3 Years: | 22% |
1 Year: | -4% |
Return on Equity | |
---|---|
10 Years: | 16% |
5 Years: | 14% |
3 Years: | 12% |
Last Year: | 9% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
21 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | |
Reserves | 75 | 140 | 145 | 188 | 256 | 442 | 537 | 657 | 817 | 949 | 1,066 | 1,213 |
207 | 186 | 167 | 115 | 101 | 54 | 67 | 35 | 28 | 28 | 35 | 34 | |
46 | 48 | 73 | 92 | 71 | 65 | 102 | 91 | 104 | 150 | 137 | 153 | |
Total Liabilities | 349 | 396 | 406 | 417 | 450 | 583 | 727 | 805 | 971 | 1,149 | 1,260 | 1,422 |
204 | 287 | 287 | 287 | 285 | 421 | 491 | 495 | 563 | 604 | 619 | 655 | |
CWIP | 60 | 2 | 2 | 5 | 7 | 8 | 11 | 10 | 10 | 10 | 15 | 16 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 111 | 124 | 121 | 102 | 360 |
84 | 107 | 117 | 125 | 158 | 153 | 226 | 188 | 275 | 414 | 524 | 392 | |
Total Assets | 349 | 396 | 406 | 417 | 450 | 583 | 727 | 805 | 971 | 1,149 | 1,260 | 1,422 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
49 | 41 | 43 | 54 | 93 | 107 | 116 | 129 | 141 | 163 | 122 | 140 | |
-187 | -40 | -25 | -15 | -10 | -60 | -60 | -124 | -43 | -27 | -19 | -298 | |
128 | -3 | -20 | -36 | -63 | -65 | -2 | -43 | -39 | -26 | -27 | -26 | |
Net Cash Flow | -10 | -2 | -1 | 2 | 21 | -18 | 54 | -38 | 60 | 109 | 75 | -184 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 70 | 65 | 49 | 61 | 52 | 55 | 55 | 51 | 61 | 63 | 61 | 68 |
Inventory Days | 222 | 318 | 387 | 403 | 358 | 352 | 339 | 363 | 361 | 346 | 402 | 343 |
Days Payable | 139 | 121 | 81 | 89 | 68 | 57 | 78 | 46 | 43 | 56 | 60 | 67 |
Cash Conversion Cycle | 152 | 262 | 356 | 374 | 342 | 351 | 315 | 369 | 379 | 353 | 404 | 344 |
Working Capital Days | 60 | 95 | 5 | -4 | 40 | 106 | 82 | 90 | 100 | 104 | 122 | 359 |
ROCE % | 28% | 26% | 12% | 25% | 37% | 32% | 26% | 25% | 23% | 23% | 16% | 12% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
25 May - Advanced Enzyme Technologies Limited has informed the exchange regarding the schedule of Analyst / Investor meeting of the Company with ICICI Prudential MF
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
25 May - Advanced Enzyme Technologies Limited has informed the exchange regarding the schedule of Analyst / Investor meeting of the Company with Banyan Tree Advisors
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
24 May - Read with SEBI Circular No. CIR/CFD/CMD1/27/2019 dated February 08, 2019, enclosed is copy of Annual Secretarial Compliance Report of the Company for the year ended …
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
19 May - Advanced Enzyme Technologies Limited has informed the exchange regarding the schedule of Analyst / Investor meeting of the Company with HDFC Mutual Fund
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
18 May - In furtherance to our intimation letter dated May 12, 2023, please find enclosed the Transcript of the Conference call held on Monday, May 15, 2023 …
Annual reports
Concalls
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Nov 2021TranscriptNotesPPT
-
Oct 2021TranscriptNotesPPT
-
Sep 2021Transcript PPT
-
Aug 2021TranscriptNotesPPT
-
Jun 2021Transcript PPT
-
Mar 2021TranscriptPPT
-
Feb 2021Transcript PPT
-
Dec 2020Transcript PPT
-
Nov 2020TranscriptNotesPPT
-
Aug 2020Transcript PPT
-
Aug 2020TranscriptNotesPPT
-
Jun 2020Transcript PPT
-
Mar 2020TranscriptPPT
-
Feb 2020Transcript PPT
-
Feb 2020TranscriptNotesPPT
-
Nov 2019Transcript PPT
-
Nov 2019TranscriptNotesPPT
-
Nov 2019TranscriptNotesPPT
-
Aug 2019Transcript PPT
-
May 2019Transcript PPT
-
Nov 2018Transcript PPT
-
Aug 2018Transcript PPT
-
Jun 2018Transcript PPT
-
May 2018TranscriptNotesPPT
-
May 2018TranscriptNotesPPT
-
May 2018TranscriptNotesPPT
-
Feb 2018Transcript PPT
-
Nov 2017Transcript PPT
-
Sep 2017TranscriptPPT
-
Jun 2017TranscriptNotesPPT
-
Jun 2017Transcript PPT
-
May 2017TranscriptNotesPPT
-
Mar 2017TranscriptNotesPPT
-
Feb 2017Transcript PPT
-
Nov 2016Transcript PPT
-
Nov 2016TranscriptPPT
Market Position
The Co. is the 1st Indian enzyme company with 2nd highest market share in India. It is the 2nd listed integrated enzyme player globally. [1]